"On June 9, French officials suspended the use of Actos (pioglitazone) and Competact (metformin with pioglitazone) after a study showed a slightly increased risk of developing bladder cancer among users.
Germany also pulled the drugs from the market.
Five days later, the US Food and Drug Administration (FDA) warned consumers that the popular diabetes drug Actos may increase the risk of bladder cancer when used for more than a year."
Germany also pulled the drugs from the market.
Five days later, the US Food and Drug Administration (FDA) warned consumers that the popular diabetes drug Actos may increase the risk of bladder cancer when used for more than a year."
No hay comentarios:
Publicar un comentario
Nota: solo los miembros de este blog pueden publicar comentarios.